National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 1081847

History of Changes from the VAERS Wayback Machine

First Appeared on 6/25/2021

VAERS ID: 1081847
VAERS Form:2
Age:
Sex:Female
Location:Foreign
Vaccinated:2021-02-11
Onset:2021-02-15
Submitted:0000-00-00
Entered:2021-03-08
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH UNKNOWN / 1 - / OT

Administered by: Other      Purchased by: ??
Symptoms: Atrial fibrillation, Blood creatinine, Body temperature, C-reactive protein, Cardiovascular disorder, Cyanosis, Dehydration, Dyspnoea, Electrocardiogram, Heart rate, Hyperkalaemia, Hypernatraemia, Oxygen saturation, Oxygen saturation decreased, Renal failure, Respiratory rate, Brain natriuretic peptide, Investigation, Coma scale, Blood pressure measurement

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died:2021-02-16
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? Yes
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Heart failure; Hypertension arterial
Preexisting Conditions: Medical History/Concurrent Conditions: Atrial fibrillation; Knee arthroplasty (PAO); Pulmonary embolism (left PE); Unspecified disorder of thyroid
Allergies:
Diagnostic Lab Data: Test Date: 20210215; Test Name: Creatinine; Result Unstructured Data: Test Result:423; Comments: renal failure with creatinine 423; Test Date: 20210215; Test Name: Blood pressure; Result Unstructured Data: Test Result:hypotension; Test Date: 20210215; Test Name: Blood pressure; Result Unstructured Data: Test Result:96/67 mmHg; Test Date: 20210215; Test Name: Body Temperature; Result Unstructured Data: Test Result:Afebrile; Test Date: 20210215; Test Name: Body Temperature; Result Unstructured Data: Test Result:37.3 Centigrade; Test Date: 20210215; Test Name: BNP; Result Unstructured Data: Test Result:1000; Comments: BNP (ventricular natriuretic protein) 1000; Test Date: 20210215; Test Name: GCS; Result Unstructured Data: Test Result:E3V2M6; Comments: obeying commands, incomprehensible speech, eye opening in response to speech; there was no localization sign; Test Date: 20210215; Test Name: C-reactive protein; Result Unstructured Data: Test Result:170; Test Date: 20210215; Test Name: ECG; Result Unstructured Data: Test Result:130 bpm; Comments: rapid atrial fibrillation (rapid ACFA) 130 bpm with diffuse repolarization disturbances; Test Date: 20210215; Test Name: Heart rate; Result Unstructured Data: Test Result:decreased; Test Date: 20210215; Test Name: Pulse; Result Unstructured Data: Test Result:60; Test Date: 20210215; Test Name: Tachycardia; Result Unstructured Data: Test Result:130; Test Date: 20210215; Test Name: Hyperkalaemia; Result Unstructured Data: Test Result:6.1; Test Date: 20210215; Test Name: Hypernatremia; Result Unstructured Data: Test Result:158; Test Date: 20210215; Test Name: Clinical examination; Result Unstructured Data: Test Result:borderline blood pressure, tachycardia 130; Comments: borderline blood pressure, tachycardia 130, afebrile, rapid BDC (rapid heart sound disturbances), no OMI (legs oedema), superficial polypnea, and bilateral crackles; Test Date: 20210215; Test Name: Clinical examination; Result Unstructured Data: Test Result:clinically dehydrated; Test Date: 20210216; Test Name: Clinical examination; Result Unstructured Data: Test Result:progressive degradation of hemodynamics; Comments: progressive degradation of hemodynamics, and with cyanosis; Test Date: 20210215; Test Name: Oxygen saturation; Result Unstructured Data: Test Result:100/2 L/min oxygen; Test Date: 20210215; Test Name: Respiratory rate; Result Unstructured Data: Test Result:20
CDC 'Split Type': FRPFIZER INC2021232772

Write-up: progressive degradation of hemodynamics; Cyanosis; AFib / rapid atrial fibrillation (rapid ACFA) 130 bpm with diffuse repolarization disturbances; Major dehydration/ clinically dehydrated; Oxygen saturation decreased/ desaturation; Dyspnoea; renal failure with creatinine 423, BNP (ventricular natriuretic protein) 1000, and CRP (C-reactive protein) 170; This is a spontaneous report from a contactable physician downloaded from the regulatory authority WEB; the Regulatory Authority Report Number is: FR-AFSSAPS-TS20210392. A 95-year-old female patient received the first dose of the BNT162B2 (COMIRNATY; lot/batch number and expiry date were unknown), intramuscular on 11Feb2021 at SINGLE DOSE for COVID-19 immunisation. The patient''s medical history included ongoing hypertension arterial and heart failure; Patient had periacetabular osteotomy (PAO), left pulmonary embolism (PE), atrial fibrillation, and dysthyroidism, all from an unknown date and unknown if ongoing. Patient was in a nursery home. Concomitant medications were not reported. On 15Feb2021, day 4 after the first dose of Comirnaty, the patient experienced a rapid outbreak of ACFA that was poorly tolerated with desaturation and major dehydration. It was reported that the patient was admitted in the emergency room for dyspnea on 15Feb2021. The patient underwent lab tests and procedures on 15Feb2021 which included: Pulse: 60, Blood pressure left arm (Max/Min): 96/67 mmHg, Oxygen saturation: 100/2 L/min oxygen, Respiratory rate: 20, and Temperature: 37.3 degrees Centigrade. Per clinical examination, patient had borderline blood pressure, tachycardia 130, afebrile, rapid BDC (rapid heart sound disturbances), no OMI (legs oedema), superficial polypnea, and bilateral crackles. GCS (Glasgow coma scale) E3V2M6 (obeying commands, incomprehensible speech, eye opening in response to speech; there was no localization sign). On ECG, the following was noted: rapid atrial fibrillation (rapid ACFA) 130 bpm with diffuse repolarization disturbances. Faced with poorly tolerated ACFA, patient was administered with 300mg cordarone over 30 min plus 80mg of lasilix. Upon reassessment, the following were observed: decrease in heart rate, hypotension, and patient was clinically dehydrated. Other laboratory assessments performed in 15Feb2021 showed hypernatremia at 158, hyperkalaemia at 6.1, renal failure with creatinine 423, BNP (ventricular natriuretic protein) 1000, and CRP (C-reactive protein) 170. The following were conducted: probabilistic antibiotic therapy by C3G (third generation cephalosporins), rehydration by NaCl 1000/24h, and anxiolysis by midazolam 0.5 mg/h. On 16Feb2021 patient had progressive degradation of hemodynamics, and with cyanosis. Comfort treatment with 0.5 mg/h of morphine was initiated and patient died on 16Feb2021 at 7:10 am. No autopsy was performed. No follow-up attempts are possible; information on lot/batch number cannot be obtained. No further information is expected.; Reported Cause(s) of Death: Oxygen saturation decreased/ desaturation; Major dehydration/ clinically dehydrated; Renal failure; AFib / rapid atrial fibrillation (rapid ACFA) 130 bpm with diffuse repolarization disturbances; progressive degradation of hemodynamics; Cyanosis

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1081847&WAYBACKHISTORY=ON

Government Disclaimer on use of this data


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166